Tricyclic Heterocycles as Selective DPP-4 Inhibitors
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for Type 2 diabetes, such as sulfonylureas and glitazones, have limitations including risk of hypoglycemia, liver toxicity, and side effects like nausea and diarrhea, while DPP-4 inhibitors offer improved insulin regulation without inappropriate insulin spikes, but there is a need for selective DPP-4 inhibitors that minimize impact on other serine peptidases.
Innovation Solution
Development of tricyclic heterocyclic compounds that act as selective DPP-4 inhibitors, specifically designed to inhibit the dipeptidyl peptidase-IV enzyme, thereby regulating insulin levels effectively without increasing the risk of hypoglycemia, and are formulated into pharmaceutical compositions for treating diabetes and related conditions.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If selective DPP-4 inhibitors are developed to improve insulin regulation, then insulin control is improved, but the complexity of achieving selectivity over other serine peptidases increases
Solution Approach 1:
The patent applies local quality by designing specific functional groups and structural features at particular positions within the tricyclic heterocycle molecule. Different regions of the molecule are optimized to interact with specific residues in the DPP-4 active site, creating localized binding characteristics that distinguish DPP-4 from other serine peptidases. This localized optimization of molecular interactions achieves selectivity without requiring complete redesign of the entire molecular structure.
Solution Approach 2:
The patent employs parameter changes by systematically varying structural parameters of the tricyclic heterocycle, including ring substitution patterns, heteroatom types, and side chain configurations. These parameter modifications allow fine-tuning of the molecule's binding affinity and selectivity profile. By changing specific structural parameters while maintaining the core tricyclic framework, the invention achieves differentiated binding to DPP-4 versus other peptidases.
2Quantity of substance
If existing treatments like sulfonylureas are used to increase insulin levels, then insulin production is improved, but the risk of hypoglycemia increases
Solution Approach 1:
The patent implements feedback control through DPP-4 inhibition, which prevents the degradation of incretin hormones (GLP-1 and GIP). These incretins naturally stimulate insulin secretion in a glucose-dependent manner, creating a feedback mechanism where insulin release is proportional to blood glucose levels. This contrasts with sulfonylureas that provide unregulated insulin stimulation, thereby reducing hypoglycemia risk while maintaining effective insulin production.
3Reliability
If glitazones are used to increase insulin sensitivity, then metabolic control is improved, but liver toxicity occurs
Solution Approach 1:
The patent extracts the beneficial metabolic effects of incretin-based therapy from the harmful liver toxicity associated with glitazones. By targeting DPP-4 inhibition rather than directly activating PPAR-gamma receptors (the mechanism of glitazones), the invention achieves improved insulin sensitivity and metabolic control through a different biochemical pathway that bypasses the hepatotoxic mechanism. This extraction of beneficial effects while eliminating harmful side effects is achieved through selective enzyme inhibition rather than receptor agonism.
Data Source
AI summary
The present invention is directed to novel tricyclic heterocycles of structural formula (I) which are inhibitors of the dipeptidyl peptidase-IV enzyme and which are useful in the treatment or prevention of diseases in which the dipeptidyl peptidase-IV enzyme is involved, such as diabetes and particularly Type 2 diabetes. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which the dipeptidyl peptidase-IV enzyme is involved.